Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791861 | 0.95 | GPR84 (0.54) | GPR84GSK3BPDE3BPDE3APARP1 | |
| SCHEMBL4016016 | 0.89 | PDE3B (0.51) | GPR84GSK3BPDE3BPDE3AMEN1 | |
| SCHEMBL3823910 | 0.80 | — | — | |
| SCHEMBL24211554 | 0.79 | GPR84 (0.42) | GPR84PDE3BPDE3AMEN1KMT2A | |
| SCHEMBL2483213 | 0.77 | PDE3B (0.42) | GPR84PDE3BPDE3AMEN1KMT2A | |
| SCHEMBL26011808 | 0.77 | MEN1 (0.39) | GPR84PDE3BPDE3AMEN1KMT2A | |
| SCHEMBL3344549 | 0.73 | MEN1 (0.58) | GPR84GSK3BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14639314 | 0.72 | — | — | |
| SCHEMBL10927286 | 0.72 | — | — | |
| SCHEMBL6294711 | 0.72 | GPR84 (0.38) | GPR84PDE3BPDE3AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102477016-A | Synthesis and application of intermediate of tapentadol | INST MATERIA MEDICA CAMS | 2012-05-30 | — | — | CN | claimed |
| US-20230006152-A1 | METAL COMPLEX AND LIGHT EMITTING DEVICE | CITY UNIVERSITY OF HONG KONG (HK) | 2023-01-05 | — | — | US | disclosed |
| US-20220402955-A1 | METAL COMPLEX AND LIGHT EMITTING DEVICE | CITY UNIVERSITY OF HONG KONG (HK) | 2022-12-22 | — | — | US | disclosed |
| CN-102477016-B | Synthesis and application of intermediate of tapentadol | INST MATERIA MEDICA CAMS | 2014-12-17 | — | — | CN | disclosed |
| CN-101573361-B | Aminopyrimidine derivatives as PLK1 inhibitors | MSD KK | 2012-05-30 | — | — | CN | disclosed |
| CN-102477016-A | Synthesis and application of intermediate of tapentadol | INST MATERIA MEDICA CAMS | 2012-05-30 | — | — | CN | disclosed |
| EP-2167489-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2167497-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| CN-101573361-A | Novel aminopyrimidine derivative as plk1 inhibitor | BANYU PHARMA CO LTD (JP) | 2009-11-04 | — | — | CN | disclosed |
| WO-2009006404-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230006152-A1 | METAL COMPLEX AND LIGHT EMITTING DEVICE | OCIAD1, OCIAD2, OPRD1 | GPR84 2045/4885GSK3B 4439/4885PDE3B 4839/4885 |
| US-20220402955-A1 | METAL COMPLEX AND LIGHT EMITTING DEVICE | OCIAD1, OCIAD2, OSTC | GPR84 1897/4885GSK3B 3819/4885PDE3B 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.